Skip to content
Monday 31 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,824.26
+0.29%
DAX
26,569.99
+0.77%
CAC 40
8,401.18
0.00%
STOXX 50
6,485.67
+0.95%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Tuesday 03 November 2015 12:06 pm

Cancer survival in London: A quarter die within two months following A&E diagnosis

By: Sarah Spickernell

Add as a preferred source on Google

Londoners diagnosed with cancer at accident and emergency departments have a very low chance of survival, new figures from Cancer Research UK show.

A quarter of people identified as having the disease at this late stage in hospitals across the capital die within two months, while the average survival is less than six months, the study found. Just 36 per cent live for more than a year.

The reason, according to the researchers, is that if cancer has gone this long without being detected, it means the disease has reached an advanced stage and is more likely to have spread to multiple parts of the body.

Read more: Scientists say immunotherapy could open a "new era" of cancer treatment

And when it reaches this level, not only are there fewer available options for treatment, but the effectiveness of any treatment is diminished.

The findings come from an analysis of 1,000 patients diagnosed with the disease at emergency units across London's 12 hospitals over the course of 2013.

Kathy Pritchard-Jones, author of the study, said this “hammers home” the need to focus on early diagnosis in the UK, as it can make a “huge difference to your chances of surviving cancer”.

Around a quarter of all cancer cases are being diagnosed following presentation in A&E and the vast majority of these are already at a late stage, when treatment options are limited and survival is poorer. And many of the patients diagnosed through A&E have other health conditions that may complicate their treatment.

We need to find ways to diagnose patients earlier, and through managed pathways. This is crucial to improving the UK's cancer survival to the standard of comparable countries.

Recognising the problem, the government is already taking steps to ensure cancer is caught earlier. In June this year, the National Institute for Health and Care Excellence (Nice), the government's health watchdog, put new guidelines in place that will “save thousands” of lives each year.

Nice is giving doctors in England basic diagnostic tests to help identify the disease in its early stages, so that patients can be referred to specialists before the symptoms become severe. GPs will have access to equipment such as CT scans and endoscopies, which are currently only available to specialists once referrals have gone ahead.

It is estimated that around 5,000 lives will be saved in England each year thanks to the earlier diagnosis that will result from this measure.

While the UK still lags behind many of its European neighbours in terms of cancer survival rates, overall the number of people getting the disease has gone down since the late 1990s. 

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Tech

Trending Articles

  • Pensioners to hand over bank statements in government benefits crackdown

  • Jamie Carragher: HMRC petitions for Sky Sports star to be declared bankrupt

  • Jamie Vardy bags Bundesliga rights as he steps up streaming war with Neville and Lineker

  • City firms mandate phone and face-to-face comms bootcamps for Gen Z lawyers

  • Brewdog founder James Watt hits out at ‘total silence’ over new venture

More from Morning Wire

  • Leeds NHS Innovation to Accelerate Global Adoption of AI-enabled Pathology for Cancer Diagnostics Through Epredia Partnership

    Business Wire
  • Prothena Reports Second Quarter 2026 Financial Results and Business Highlights

    Business Wire
  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • Thames Water faces fresh threat to survival after pensions regulation breach

    Water
    Thames Water infrastructure with pipes and maintenance workers, highlighting water management efforts in London
  • Mary Kay’s Pink Changing Lives® Program Turns Purpose Into Measurable Impact for Women Around the World

    Business Wire
  • Astrazeneca share price tumbles on $400bn megamerger talks

    Investing
    Astrazeneca headquarters with logo, reflecting commitment to reduce US medicine prices after Trump administration pressure
  • Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

    Business Wire
  • Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook